---

Note: Since you skipped topic selection, I've chosen Sepsis and Septic Shock - the single most important topic for MBBS/junior doctor training. It covers every domain you requested: ICU protocols, hemodynamics, electrolytes, emergencies, guidelines, and clinical reasoning. If you wanted a different topic, just tell me and I'll rebuild it.

---

SEPSIS & SEPTIC SHOCK

Complete Clinical Teaching Module for Junior Doctors

---

PART 1 - DEFINITION & EPIDEMIOLOGY

Sepsis-3 Definitions (2016 - Current Standard)

Mortality: Sepsis ~10-15%, Septic Shock ~40%. Importantly, sepsis mortality has been declining (19% in 2009 to ~15% in 2014) despite stable incidence - attributed to protocol-driven care.

---

PART 2 - PATHOPHYSIOLOGY (The "Why" Behind Every Treatment)

INFECTION
    ↓
Pathogen Recognition (TLRs, NLRs, pattern recognition receptors)
    ↓
Activated myeloid cells (neutrophils, macrophages, monocytes)
    ↓
Cytokine storm: TNF-α, IL-1, IL-6, IL-8
    ↓
┌─────────────────────────────────────────────────┐
│  Endothelial damage → capillary leak → edema    │
│  ↓ SVR (vasodilation) → distributive shock      │
│  Myocardial depression (septic cardiomyopathy)  │
│  Microvascular thrombosis → DIC                 │
│  Mitochondrial dysfunction → lactic acidosis    │
└─────────────────────────────────────────────────┘
    ↓
Multi-Organ Dysfunction Syndrome (MODS)
(Lungs: ARDS | Kidneys: AKI | Brain: Encephalopathy | Liver: Cholestasis | Adrenals: Relative insufficiency)

• Septic shock is distributive - high CO, low SVR (warm shock early)
• Despite high CO, tissues cannot extract oxygen properly ("cytopathic hypoxia")
• Lactic acidosis occurs even with normal BP due to mitochondrial failure, not just hypoperfusion
• Late septic shock may also have myocardial depression (low CO phase)

---

PART 3 - DIAGNOSIS & SCORING TOOLS

SOFA Score (Sequential Organ Failure Assessment)

qSOFA (Quick Bedside Screening - no labs needed)

Common Sources of Infection (MBBS Mnemonic: LURASI)

• Lung (pneumonia - 33%)
• Urinary tract (UTI/urosepsis - 49%)
• Residual (intraabdominal/gut - 14%)
• Abdominal (bowel perforation, cholangitis)
• Skin/soft tissue (cellulitis, wounds - 10%)
• Intravenous line (catheter-related bloodstream infection)

---

PART 4 - INVESTIGATIONS

Bedside / Emergency Panel

Electrolytes Specifically

---

PART 5 - HEMODYNAMIC GOALS & MONITORING

Hemodynamic Targets (SSC 2026 + Harrison's 22E)

Dynamic Measures of Volume Responsiveness (Better than CVP)

Monitoring Parameters (ICU Checklist)

CONTINUOUS:
  ✓ ECG monitoring (rhythm, rate)
  ✓ SpO₂ (pulse oximetry)
  ✓ Arterial line → continuous BP, ABG access
  ✓ CVP (if CVC in place)

HOURLY:
  ✓ Urine output (Foley catheter mandatory)
  ✓ Temperature
  ✓ GCS / mental status

EVERY 2-4 HOURS:
  ✓ Lactate (until normalized)
  ✓ Glucose
  ✓ ABG (if mechanically ventilated)

DAILY:
  ✓ CBC, electrolytes, renal/hepatic function
  ✓ Coagulation (if DIC concern)
  ✓ PCT trend (antibiotic de-escalation)
  ✓ Chest X-ray
  ✓ SOFA score reassessment

---

PART 6 - MANAGEMENT PROTOCOLS

THE SEPSIS HOUR-1 BUNDLE (SSC 2021/2026)

This is the most exam-tested and clinically critical content. Memorize this.

Within 1 HOUR of Recognition:

1. MEASURE LACTATE → If >2 mmol/L, re-measure after resuscitation
2. BLOOD CULTURES ×2 → Before antibiotics (one peripheral + one CVC site if available)
3. ANTIBIOTICS → Broad-spectrum IV within 1 hour (septic shock) or 3 hours (sepsis)
4. IV FLUIDS → 30 mL/kg crystalloid bolus if hypotension or lactate ≥4 mmol/L
5. VASOPRESSORS → Start norepinephrine if MAP <65 despite initial fluids

• Lactate measure
• Blood cultures
• Launch antibiotics
• Administer fluids
• Vasopressors if needed

---

FLUID RESUSCITATION

---

VASOPRESSOR PROTOCOL (SSC 2026)

STEP 1: Norepinephrine (NE) → FIRST-LINE
  Dose: 0.01-3.3 mcg/kg/min IV infusion
  Start at: 0.01-0.05 mcg/kg/min, titrate to MAP ≥65
  
  ↓ If MAP still <65 at moderate NE dose:
  
STEP 2: ADD Vasopressin 0.03-0.04 units/min (fixed dose, do NOT titrate)
  - Spares NE dose
  - May reduce AKI risk
  
  ↓ If still not at goal:
  
STEP 3: ADD Epinephrine
  - Use when cardiac dysfunction coexists
  - Increases HR, contractility, AND vasoconstriction
  
SPECIAL:
  Dobutamine → Add to NE if myocardial dysfunction (low CO + evidence of hypoperfusion)
  Angiotensin II → Considered for refractory vasodilatory shock
  
AVOID:
  ✗ Dopamine as first-line (higher arrhythmia risk vs. NE - SSC 2026)
  ✗ Phenylephrine in septic shock (decreases CO)

---

ANTIBIOTIC PROTOCOL

---

CORTICOSTEROIDS

• Drug: Hydrocortisone 200 mg/day IV (50 mg q6h OR 200 mg continuous infusion)
• Do NOT use dexamethasone (suppresses HPA axis cortisol testing)
• ACTH stimulation test NOT required before starting
• Duration: Until vasopressors weaned
• Mechanism: Relative adrenal insufficiency in ~50% of septic shock patients; steroid restores vascular responsiveness to catecholamines

---

BLOOD GLUCOSE MANAGEMENT

---

PART 7 - ESCALATION OF CARE

When to Escalate from Ward to ICU

Respiratory Escalation Algorithm

Hypoxemia in Sepsis
        ↓
SpO₂ <94% → Nasal cannula 2-6 L/min
        ↓ if inadequate
Simple face mask 6-10 L/min
        ↓ if inadequate
Non-rebreather mask 10-15 L/min
        ↓ if inadequate
HIGH-FLOW NASAL CANNULA (HFNC) - preferred over NIV (SSC 2026)
  Flow: 40-60 L/min | FiO₂ titrated
        ↓ if SpO₂ <90% or WOB ↑
INTUBATION + MECHANICAL VENTILATION
  (Lung-protective: Vt 6 mL/kg IBW, Plateau P <30 cmH₂O)
        ↓ if refractory (PaO₂/FiO₂ <150)
PRONE POSITIONING (16 hours/day)
NEUROMUSCULAR BLOCKADE
VV-ECMO (tertiary center)

---

PART 8 - COMPLICATIONS

Early Complications (First 24-72 Hours)

Late Complications (After Acute Phase)

Prevention of Complications

DIC/Bleeding: Early antibiotics + source control
AKI: Maintain MAP ≥65, avoid nephrotoxins, balanced crystalloids
VAP: Head-of-bed elevation 30-45°, daily sedation holds, early extubation
DVT/PE: Pharmacological VTE prophylaxis (heparin) - SSC 2026 recommends pharmacologic alone
Stress ulcer: Proton pump inhibitor (consider if on mechanical ventilation)
ICUAW: Early physiotherapy, minimize sedation

---

PART 9 - PROTOCOLS BY SETTING

OPD Protocol (Walk-In Patient with Possible Sepsis)

Patient presents with fever + altered general condition

STEP 1: SCREEN (2 min)
  - Check qSOFA: Altered sensorium? RR ≥22? SBP ≤100?
  - Temp, HR, BP, SpO₂, RR at triage

STEP 2: TRIAGE DECISION
  qSOFA 0-1 + hemodynamically stable:
    → Blood work (CBC, CRP, cultures), urine culture
    → Oral antibiotics if bacterial infection confirmed
    → Return precautions clearly explained
    → Follow-up in 24h
    
  qSOFA ≥2 OR SBP <90 OR any organ dysfunction:
    → DO NOT discharge → Call ambulance / transfer to ED immediately
    → IV access en route
    → O₂ supplementation

⚠️ SAFETY RULE: Never send a septic patient home with oral antibiotics if they have
evidence of organ dysfunction. This requires hospital admission.

Ward Protocol (Admitted Patient Developing Sepsis)

Ward patient → Nurse notices: fever spike + tachycardia + confusion

STEP 1: RAPID ASSESSMENT (0-15 min)
  → Vital signs Q15 min
  → GCS, urine output check
  → IV access (large bore ×2)
  → O₂ via face mask, SpO₂ monitor

STEP 2: INVESTIGATIONS (simultaneous)
  → Blood cultures ×2 (BEFORE antibiotics)
  → CBC, metabolic panel, lactate, coagulation
  → CXR (portable)
  → Urinalysis + culture
  → ECG

STEP 3: CALL DOCTOR + IMPLEMENT
  → Notify registrar/consultant IMMEDIATELY
  → 30 mL/kg crystalloid bolus over 30-60 min (if not contraindicated)
  → Broad-spectrum antibiotics WITHIN 1 HOUR
  → Catheterize (urine output monitoring)

STEP 4: REASSESS (1h mark)
  → MAP <65 despite fluids → Transfer to HDU/ICU, start vasopressors
  → Lactate not clearing → ICU
  → SpO₂ <90% → Escalate O₂, ICU referral
  → Response to treatment → Continue ward management with close monitoring

ICU Protocol (Septic Shock Patient)

ICU ADMISSION CHECKLIST:
  □ Arterial line (continuous BP + ABG access)
  □ Central venous catheter (CVC) - right internal jugular or subclavian
  □ Foley catheter (hourly urine output)
  □ NGT (nutrition)
  □ Continuous ECG + SpO₂
  □ Point-of-care ECHO (assess volume status, LV function)

BUNDLE COMPLIANCE AUDIT (Hour 1):
  □ Lactate measured?
  □ Blood cultures × 2 drawn?
  □ Broad-spectrum antibiotics given?
  □ 30 mL/kg fluid given?
  □ Vasopressors started if MAP <65?

ONGOING ICU MANAGEMENT:
  □ Vasopressor titration to MAP ≥65
  □ Lactate q2h until <2 mmol/L
  □ Glucose monitoring q1-2h (target 140-180 mg/dL)
  □ Electrolyte correction (K⁺, Mg²⁺, Ca²⁺, PO₄)
  □ Lung-protective ventilation if intubated (Vt 6 mL/kg IBW)
  □ Daily sedation hold + SAT/SBT protocol
  □ VTE prophylaxis (heparin 5000 U SC q8-12h)
  □ Stress ulcer prophylaxis (PPI)
  □ Early enteral nutrition (within 24-48h, SSC 2026: within 72h)
  □ Daily SOFA score recalculation
  □ Antibiotic de-escalation based on cultures + PCT trend
  □ Source control (drain abscess, remove infected catheter)

Emergency Protocol (ED Presentation)

CODE SEPSIS - Activation Criteria:
  Suspected infection + ≥2 of: Temp >38.3 or <36°C | HR >90 | RR >20 | Altered sensorium

TIME ZERO (Recognition):
  0 min: Two large-bore IVs | O₂ | Monitor | Glucose check
  5 min: Blood cultures ×2 | Lactate | CBC | CMP | Coag
  15 min: CXR (portable) | ECG | UA | IV fluids RUNNING
  30 min: Antibiotics IN (don't wait for culture results)
  60 min: Reassess MAP + lactate
           ↓ If MAP <65 → Vasopressors (NE via CVC or peripheral large bore)
           ↓ If SpO₂ <90% → HFNC or NIV
           ↓ If GCS declining → RSI + intubation

DOCUMENTATION: Time of recognition, time of antibiotics, time of cultures, 
  fluid volumes, vasopressor start time (medicolegal and audit purposes)

---

PART 10 - GUIDELINES & SOURCES

---

PART 11 - CLINICAL PEARLS FOR EXAMS & VIVA

High-Yield MBBS Exam Points

1. Sepsis-3 definition: Sepsis = infection + SOFA ≥2; Septic shock = sepsis + vasopressor + lactate >2 despite fluids
2. Most common source: Urinary tract (48.9%) followed by respiratory (32.9%)
3. Most common organisms: Gram+ = S. aureus, Streptococcus; Gram- = E. coli, Klebsiella, Pseudomonas
4. First-line vasopressor: Norepinephrine (NOT dopamine - SSC 2026)
5. Fluid of choice: Balanced crystalloid (Lactated Ringer's > Normal Saline)
6. NEVER give HES (hydroxyethyl starch) - increases mortality
7. Glucose target: 140-180 mg/dL (not normal range - NICE-SUGAR)
8. Corticosteroids: Only if vasopressor-dependent; Hydrocortisone 200 mg/day
9. Antibiotics: WITHIN 1 hour in septic shock; don't wait for culture results
10. Septic shock mortality: ~40-50% despite treatment

Common Student Mistakes

Frequently Asked Viva Questions

1. "What is the difference between Sepsis-2 and Sepsis-3?"
   • Sepsis-2 used SIRS criteria (too non-specific). Sepsis-3 uses SOFA score (organ dysfunction focused) and eliminated "severe sepsis" as a term.
2. "Why is lactate important in sepsis?"
   • Lactate >2 mmol/L = tissue hypoperfusion; Lactate >4 = very high mortality. Used for diagnosis of septic shock (even with normal BP) and as a resuscitation endpoint (target clearance). Limitation: liver/kidney failure can impair clearance.
3. "What is qSOFA and when do you use it?"
   • Quick bedside screen (no labs): altered sensorium + RR ≥22 + SBP ≤100. Score ≥2 = high risk. Use in wards/ED triage, not in ICU.
4. "Why not use dopamine in septic shock?"
   • Higher risk of atrial fibrillation and arrhythmias vs. norepinephrine. A 2012 meta-analysis showed dopamine associated with higher 28-day mortality. NE is cleaner, predictable, and preferred.
5. "What is relative adrenal insufficiency?"
   • In septic shock, the adrenal glands may produce insufficient cortisol for the degree of stress, even if absolute cortisol levels are "normal." Results in catecholamine-refractory vasodilation. Treated with hydrocortisone.

---

PART 12 - CASE-BASED LEARNING

---

CASE 1 - OPD Scenario

1. Calculate his qSOFA score. What does it mean?
2. What is the most likely source of sepsis?
3. What is your IMMEDIATE next step in this OPD?
4. What investigations would you order?
5. Would you discharge him on oral antibiotics? Why or why not?

---

CASE 2 - Ward Scenario

1. What are your first three actions in the next 5 minutes?
2. What sepsis criteria does she meet?
3. What is the most likely source?
4. Write the antibiotic order for her.
5. When do you call for ICU transfer?

---

CASE 3 - ICU Scenario

• Norepinephrine 0.25 mcg/kg/min
• Ventilator (assist control, Vt 420 mL, IBW 70 kg, FiO₂ 0.6, PEEP 8)
• Current vitals: MAP 62, HR 104, SpO₂ 91%, urine output 18 mL in last hour
• Labs: K⁺ 3.1 mEq/L, Creatinine 2.8 (baseline 1.0), Lactate 3.8, Glucose 220 mg/dL, Platelets 62,000

1. Is he meeting hemodynamic goals? What is not at target?
2. What is his approximate SOFA score for the renal component?
3. What would you do about his potassium?
4. What changes would you make to his ventilator?
5. He develops petechiae and oozing from IV sites. What complication do you suspect and how do you confirm it?

---

PART 13 - VISUAL SUMMARY (MIND MAP)

                        SEPSIS & SEPTIC SHOCK
                               │
        ┌──────────────────────┼──────────────────────┐
        │                      │                      │
   DEFINITION              DIAGNOSIS              MANAGEMENT
   Sepsis-3:               qSOFA ≥2               LBLAV Bundle
   SOFA ≥2 +               SOFA ≥2                (Hour-1)
   infection               Lactate                │
        │                  Blood cx               ├─ Fluids: LR 30mL/kg
   Septic Shock:           POCUS                  ├─ Antibiotics <1h
   +vasopressors +                                ├─ NE vasopressor
   lactate >2                                     ├─ Source control
        │                                         └─ Steroids if needed
        │
   COMPLICATIONS
   ├─ Early: ARDS, AKI, DIC, Septic cardiomyopathy
   └─ Late: PICS, ICUAW, CKD, PTSD
        │
   MONITORING
   ├─ MAP ≥65, UO ≥0.5 mL/kg/h
   ├─ Lactate clearance
   ├─ ScvO₂ ≥70%
   └─ SOFA daily

---

SAFETY DISCLAIMER

Educational Use Only. This content is for learning purposes. All clinical decisions - including antibiotic selection, vasopressor dosing, fluid management, and ICU admission - must be made by a qualified, licensed physician with full knowledge of the patient's clinical status. Drug doses given are standard references; always verify against current formularies and local protocols before prescribing.

---

From Basics to ICU Management

---

"Humanity has but three great enemies: Fever, famine, and war; of these by far the greatest, by far the most terrible, is fever." — William Osler, 1896 (writing about malaria)

---

PART 1 - THE BASICS: ETIOLOGY & EPIDEMIOLOGY

The Five Species That Infect Humans

• Estimated 249 million cases in 85 endemic countries
• 608,000 deaths (~1,660 deaths every single day)
• Africa bears ~95% of deaths - mostly children under 5
• Democratic Republic of Congo + Nigeria = 43% of global deaths
• ~88% of cases are community-onset (within 48h of hospitalization)

• Primary: Bite of female Anopheles mosquito (dusk to dawn biting)
• Blood transfusion (transfusion malaria)
• Needle-sharing (IV drug users)
• Congenital / transplacental (mother → fetus)
• Organ transplantation
• "Airport malaria" (imported infected mosquito)

---

PART 2 - LIFE CYCLE (The Foundation of Everything)

The Complete Life Cycle

MOSQUITO STAGE (Sexual Cycle - in Anopheles mosquito)
    Female Anopheles bites infected human → ingests gametocytes
    Gametocytes → zygote → ookinete → oocyst → sporozoites
    Sporozoites migrate to salivary glands
           ↓ (mosquito bites human)

HUMAN STAGE 1: HEPATIC (Exoerythrocytic / Pre-erythrocytic)
    Sporozoites → bloodstream → liver (within minutes)
    Surface proteins (thrombospondin-related adhesive protein +
    circumsporozoite protein) bind hepatocyte proteoglycans
    1 sporozoite → 10,000 to >30,000 merozoites (amplification!)
    Incubation: P. falciparum 5.5 days | P. vivax 8 days |
                P. ovale 9 days | P. malariae 15 days
    
    ★ P. vivax & P. ovale → some parasites become HYPNOZOITES
      (dormant in liver) → cause RELAPSE months to years later
    
    Hepatocytes rupture → merozoites released into bloodstream
           ↓

HUMAN STAGE 2: ERYTHROCYTIC (Asexual Cycle - in RBCs)
    Merozoite binds RBC via lectin-like molecule + glycophorin/
    sialic acid residue
    Merozoite enters RBC in "digestive vacuole"
    Ring form → Trophozoite → Schizont
    
    P. falciparum schizonts express PfEMP1 (knobs on RBC surface)
    PfEMP1 binds ICAM-1, VCAM-1, CD36 on endothelium
    → CYTOADHERENCE → sequestration in capillaries → ORGAN DAMAGE
    
    Schizont ruptures → releases 6-20 new merozoites (every 48h)
    Synchronized rupture → FEVER PAROXYSM
    
    Some trophozoites → GAMETOCYTES (restart cycle if mosquito bites)

Mnemonic for the Life Cycle: "Some Monkeys Have Erythrocytic Games"

• Sporozoites (inoculated)
• Merozoites (from liver)
• Hypnozoites (dormant - vivax/ovale only)
• Erythrocytic cycle (RBC invasion)
• Gametocytes (sexual forms - infect mosquito)

---

PART 3 - PATHOPHYSIOLOGY (WHY Patients Get Sick)

How P. falciparum Kills - Six Mechanisms

1. CYTOADHERENCE
   PfEMP1 knobs → bind ICAM-1/VCAM-1/CD36 on endothelium
   → Parasitized RBCs clog capillaries (especially brain, gut, kidney)
   → CEREBRAL MALARIA (most feared complication)
   → Tissue hypoxia + ischemia

2. ROSETTING
   Infected RBCs bind uninfected RBCs → "rosettes"
   → Worsens microvascular obstruction

3. HEMOLYSIS
   RBC lysis every 48h → Anemia
   Hemoglobin release → Hemoglobinuria ("blackwater fever")
   Jaundice from hemolysis
   
4. CYTOKINE STORM
   TNF-α, IL-1, IL-6, IL-10 released during schizont rupture
   → Fever, rigors, headache, myalgia
   → Hypoglycemia (TNF-α stimulates insulin release + parasite
     consumes glucose)
   → Pulmonary edema (capillary leak)

5. IMMUNOPATHOLOGY
   Malarial antigen → immune complex formation
   P. malariae → quartan nephrotic syndrome (membranoproliferative GN)

6. METABOLIC ACIDOSIS
   Lactate accumulation (cytoadherence blocks flow)
   Parasite glycolysis consumes glucose → hypoglycemia
   Quinine/quinidine → further hypoglycemia (stimulates insulin)

---

PART 4 - CLINICAL FEATURES

The Classic Malaria Paroxysm (Synchronized schizogony)

Cold Stage (15-60 min)
    Sudden chills, rigors, teeth chattering, gooseflesh
    Temperature RISING
         ↓
Hot Stage (2-6 hours)
    High fever (39-41°C), headache, myalgia, nausea, vomiting
    Flushed, dry skin
         ↓
Sweating Stage (2-4 hours)
    Profuse diaphoresis, temperature falls dramatically
    Patient feels exhausted but better

Fever Periodicity by Species

Clinical pearl: In early P. falciparum infection, fever is often CONTINUOUS or IRREGULAR (not cyclical) because schizogony is not yet synchronized. Never rule out malaria because the fever "doesn't fit the pattern."

Symptoms by System

---

PART 5 - SEVERE MALARIA (The Emergency)

WHO Criteria for Severe Falciparum Malaria

Relative Incidence of Complications (Harrison's 22E)

• Seen almost exclusively with P. falciparum
• Mechanism: cytoadherence of parasitized RBCs in cerebral capillaries → microvascular obstruction + blood-brain barrier disruption + neuroinflammation
• Features: unarousable coma, symmetric UMN signs, retinal hemorrhages (Malarial retinopathy - PATHOGNOMONIC for cerebral malaria)
• Up to 10% of survivors have permanent neurological sequelae
• In children: hypoglycemia, seizures, and brainstem herniation are immediate threats

---

PART 6 - DIAGNOSIS

Diagnostic Modalities

Blood Film Findings by Species (Microscopy Pearls)

Microangiopathic Hemolytic Anemia on PBS

Investigations to Order

MANDATORY IN ALL SUSPECTED MALARIA:
  □ Blood films ×3 (thick + thin, Giemsa stained)
  □ RDT (HRP2/pLDH)
  □ CBC with differential
  □ Blood glucose (STAT - check immediately in severe cases)
  □ Renal function (creatinine, BUN, electrolytes)
  □ LFTs + bilirubin (total, direct, indirect)
  □ Blood cultures (rule out concurrent bacteremia)

IN SUSPECTED SEVERE MALARIA (ADD):
  □ ABG / VBG (lactate, pH, bicarbonate)
  □ Coagulation profile (PT, aPTT, fibrinogen, D-dimer) - DIC screen
  □ Serum lactate
  □ Blood glucose Q1-2h (hypoglycemia monitoring)
  □ Chest X-ray (ARDS screening)
  □ ECG (QTc prolongation if using quinine/quinidine)
  □ Urine dipstick + microscopy (hemoglobinuria)
  □ Fundoscopy (malarial retinopathy in cerebral malaria)
  □ Lumbar puncture (if meningism - exclude bacterial meningitis)

---

PART 7 - TREATMENT PROTOCOLS

The Decision Algorithm

Suspected Malaria (Fever + History of Travel/Endemic Area)
           ↓
Confirm with Blood Film + RDT
           ↓
    ┌──────────────────┐
    │                  │
Uncomplicated        Severe Malaria
  Malaria            (Any WHO criterion)
    │                  │
    ↓                  ↓
Species?           EMERGENCY PROTOCOL
    │              (See Part 8 - ICU)
    ├── P. falciparum → ACT (first-line)
    ├── P. vivax/ovale → CQ + Primaquine
    ├── P. malariae → Chloroquine alone
    └── P. knowlesi → ACT or CQ if sensitive

---

UNCOMPLICATED FALCIPARUM MALARIA - ACT (WHO 2024/2025)

Why combinations? Artemisinin components have a very short half-life (~1 hour). They rapidly reduce parasite biomass (>99.9% reduction in 48h), but the partner drug eliminates residual parasites and prevents resistance. Never use artemisinin monotherapy.

---

UNCOMPLICATED P. VIVAX / P. OVALE MALARIA

• Chloroquine 25 mg base/kg over 3 days:
  • Day 1: 10 mg/kg, Day 2: 10 mg/kg, Day 3: 5 mg/kg
  • OR ACT where chloroquine resistance exists (parts of Southeast Asia, Oceania)

Critical: If G6PD status unknown or deficient, you can still give chloroquine for blood-stage disease, but DELAY primaquine until G6PD testing. Weekly low-dose primaquine (0.75 mg/kg/week × 8 weeks) is an alternative in mild G6PD deficiency under supervision.

---

P. MALARIAE TREATMENT

• Chloroquine alone (same dosing as vivax) - no radical cure needed (no hypnozoites)
• Rare recrudescences managed by retreatment

---

DRUG RESISTANCE MAP (Important for Boards & Practice)

---

PART 8 - SEVERE MALARIA: ICU PROTOCOL

Severe Malaria = MEDICAL EMERGENCY - Call ICU Immediately

IMMEDIATE ACTIONS (0-15 minutes):
  □ Establish IV access (2 large-bore IVs)
  □ Check blood glucose STAT → treat hypoglycemia immediately
  □ Blood films + RDT STAT
  □ Start ARTESUNATE IV (do not wait for films if clinical suspicion high)
  □ Oxygen supplementation
  □ Foley catheter (hourly urine output)
  □ Connect to cardiac monitor + SpO₂
  □ NGT if unconscious (prevents aspiration + drug delivery)

Parenteral Artesunate - Drug of Choice for Severe Malaria (WHO 2024)

ARTESUNATE IV (Preferred - FDA approved, WHO first-line):
  Adults and children ≥20 kg:
    Loading: 2.4 mg/kg IV at 0h, 12h, 24h
    Then: 2.4 mg/kg IV daily until oral therapy possible

  Children <20 kg:
    3 mg/kg per dose (same timing)

  Route: IV (preferred) or IM if IV not possible
  Given in: 5-10% dextrose (to prevent hypoglycemia)

IF ARTESUNATE UNAVAILABLE:
  Artemether 3.2 mg/kg IM stat → 1.6 mg/kg IM daily
  (Note: erratic absorption, inferior to artesunate)

LAST RESORT:
  Quinine dihydrochloride: 20 mg/kg IV over 4h (loading), then
  10 mg/kg over 2-8h q8h
  ★ Risk: QTc prolongation, hypoglycemia
  ★ Must give with glucose infusion (10% dextrose)
  ★ ECG monitoring mandatory
  ★ Do NOT give loading dose if patient received quinine in last 24h

ARTEMISININ RESISTANCE AREA:
  Give BOTH artesunate + quinine together at full doses

ICU Management Checklist

HEMODYNAMIC GOALS:
  □ MAP ≥65 mmHg (isotonic fluids cautiously - risk of pulmonary edema)
  □ CAUTION: Aggressive fluid resuscitation → precipitates pulmonary edema
    (reduced plasma oncotic pressure in severe anemia + increased
    vascular permeability)
  □ Vasopressors (norepinephrine) if fluid-unresponsive shock

CEREBRAL MALARIA:
  □ Nurse head-end of bed 30° elevation
  □ Maintain airway - intubate if GCS ≤8 (unable to protect airway)
  □ Treat seizures with IV diazepam 0.15 mg/kg or IV lorazepam
  □ Avoid phenobarbitone prophylaxis (shown to increase mortality
    in African children despite stopping seizures)
  □ Monitor ICP if facilities available
  □ ✗ NO high-dose steroids (PROVEN HARMFUL in cerebral malaria -
    increases coma duration and GI bleeding)
  □ ✗ NO heparin, NO dextran, NO anti-TNF-α (all ineffective)

HYPOGLYCEMIA:
  □ Check glucose Q1-2h continuously
  □ Give 50% dextrose 1 mL/kg IV if glucose <40 mg/dL, then
    continuous 10% dextrose infusion
  □ Double risk with quinine therapy (stimulates insulin release)
  □ Highest risk: pregnant women + children + quinine-treated patients

ANEMIA:
  □ Hb <7 g/dL in adults (or Hb <5 g/dL) → transfuse packed RBCs
  □ In children: Hb <5 g/dL (with signs of impaired consciousness,
    respiratory distress, hyperparasitemia) → transfuse
  □ Transfuse slowly (risk of fluid overload in severe anemia)
  □ Use fresh blood where possible

ACUTE KIDNEY INJURY:
  □ Maintain MAP ≥65
  □ Avoid nephrotoxins (aminoglycosides, NSAIDs, IV contrast)
  □ Monitor creatinine and urine output Q1h
  □ Hemodialysis / peritoneal dialysis if renal failure
    (dialysis reduces mortality from 75% to <50%)
  □ Furosemide NOT routinely recommended (no mortality benefit)

PULMONARY EDEMA / ARDS:
  □ Sit patient upright, oxygen
  □ Intubate early if SpO₂ <90%
  □ Lung-protective ventilation: Vt 6 mL/kg IBW, plateau P <30
  □ Prone positioning if PaO₂/FiO₂ <150
  □ Strict fluid balance (negative where possible in ARDS)

COAGULOPATHY / DIC:
  □ Correct with FFP (4 units), cryoprecipitate (fibrinogen <1.5 g/L)
  □ Platelet transfusion if <50,000/µL + active bleeding
  □ ✗ Heparin NOT recommended in malarial DIC

MONITORING PARAMETERS:
  □ Glucose Q1-2h
  □ Parasitemia Q12-24h until <1%
  □ Hb + Hematocrit Q6-12h
  □ Renal function daily
  □ ECG Q8h if on quinine (QTc monitoring)
  □ Urine output hourly
  □ GCS/neurological assessment Q1-2h
  □ Temperature + vital signs Q1h

---

PART 9 - MONITORING PARAMETERS (Summary Table)

---

PART 10 - ELECTROLYTE MANAGEMENT IN MALARIA

---

PART 11 - COMPLICATIONS

Early Complications

Late Complications

---

PART 12 - MALARIA IN SPECIAL POPULATIONS

Malaria in Pregnancy

• Falciparum malaria is MUCH more dangerous in pregnancy
• Fetal loss, premature labor, low birth weight (~170g reduction), maternal death
• P. vivax also reduces birth weight (~110g)
• Placental malaria: parasites accumulate in placental microcirculation (often asymptomatic in endemic areas)

Malaria in Children

• Children under 5 = highest mortality group worldwide
• Cerebral malaria, severe anemia, convulsions, and hypoglycemia are most common
• Rapid neurological deterioration - reassess Q1-2h
• Dose artesunate 3 mg/kg (not 2.4 mg/kg) in children <20 kg
• Pre-referral rectal artesunate suppository: 10 mg/kg single dose → given in community before transport to hospital

---

PART 13 - PROTOCOLS BY SETTING

OPD Protocol

Patient: Fever + travel history to endemic area (or resident in endemic area)

STEP 1: SCREEN (5 min)
  - Vital signs: Temp, HR, BP, RR, SpO₂
  - Any danger signs? (Altered consciousness? Seizures? Vomiting everything?
    Unable to sit? Jaundice? Dark urine? Breathing difficulty?)

If NO danger signs → Proceed with outpatient workup
If ANY danger sign → URGENT referral to hospital IMMEDIATELY

STEP 2: INVESTIGATIONS
  □ Blood film (thick + thin, Giemsa)
  □ RDT if film unavailable
  □ Blood glucose (STAT - before any treatment)
  □ CBC

STEP 3: TREAT UNCOMPLICATED MALARIA
  □ Artemether-lumefantrine (AL) × 3 days (with food)
  □ Paracetamol (NOT aspirin in children - Reye's syndrome risk)
  □ Oral rehydration (plenty of fluids)
  □ For P. vivax/ovale: Add primaquine after G6PD test

STEP 4: SAFETY NETTING
  □ Return immediately if: unable to keep tablets down,
    worsening fever, confusion, dark urine, difficulty breathing
  □ Review in 24-48h
  □ Follow-up blood film on Day 3 and Day 28 (treatment response + cure)

⚠️ NEVER send home if ANY WHO severe malaria criteria present
⚠️ Do NOT give oral treatment if vomiting (→ admit for IV artesunate)

Ward Protocol

Admitted patient with confirmed/suspected malaria

ON ADMISSION:
  □ Vital signs Q4h
  □ Blood glucose Q4-6h
  □ Twice-daily clinical reassessment
  □ Parasitemia check on Days 2 and 3

UNCOMPLICATED MALARIA ON WARD:
  □ Oral ACT (AL, DHA-PPQ, or ASMQ per local protocol)
  □ Monitor for treatment failure (parasitemia not falling by 75%
    at 48h → consider resistance/non-compliance)
  □ Regular blood glucose monitoring if vomiting or on quinine
  □ Observe for at least 24h before discharge in non-immune patients

ESCALATION CRITERIA (Ward → ICU):
  □ GCS drops below 14
  □ Seizure
  □ Unable to swallow oral medication (→ IV artesunate)
  □ Hypoglycemia (<40 mg/dL)
  □ Oliguria (<0.5 mL/kg/h for 2h)
  □ SpO₂ <94% despite O₂
  □ Parasitemia increasing at 48h despite treatment
  □ Development of any WHO severe malaria criterion

Emergency Protocol (ED)

Patient in ED with suspected severe malaria

TIME ZERO:
  □ IV access × 2
  □ Blood glucose STAT → treat immediately if low
  □ Blood films × 2 sites + RDT
  □ Full blood work (CBC, renal, LFTs, coag, ABG, lactate, blood cultures)
  □ O₂ supplementation (target SpO₂ ≥94%)
  □ ECG

WITHIN 30 MINUTES:
  □ Artesunate IV 2.4 mg/kg (or 3 mg/kg if child <20 kg)
  □ 10% dextrose infusion running (prevents hypoglycemia)
  □ Foley catheter (hourly UO)

WITHIN 1 HOUR:
  □ Reassess GCS, vitals, glucose
  □ If cerebral malaria → arrange ICU transfer
  □ If unable to protect airway (GCS ≤8) → RSI + intubation
  □ Treat seizures (IV diazepam)
  □ If blood glucose <40 mg/dL → 50% dextrose 1 mL/kg IV bolus
  □ Blood transfusion if Hb <7 g/dL (adults) or <5 g/dL (children)

ADMIT ALL FALCIPARUM MALARIA:
  Uncomplicated → Ward
  Any severe criterion → ICU

---

PART 14 - PREVENTION

Personal Protection (Individual Level)

Chemoprophylaxis (Travelers + High-Risk Individuals)

Intermittent Preventive Treatment (IPT) - Public Health

Vaccines (New and Emerging)

---

PART 15 - GUIDELINES & SOURCES

---

PART 16 - CLINICAL PEARLS & EXAM PREPARATION

High-Yield MBBS Exam Points

1. Most dangerous species: P. falciparum (cytoadherence via PfEMP1)
2. Relapse species: P. vivax and P. ovale (hypnozoites in liver)
3. Recrudescence: P. malariae (sub-patent persistence, no hypnozoites)
4. Banana-shaped gametocytes: PATHOGNOMONIC for P. falciparum
5. Band-form trophozoites: PATHOGNOMONIC for P. malariae
6. Schüffner's dots + enlarged RBCs: P. vivax and P. ovale
7. Drug of choice - Uncomplicated falciparum: ACT (Artemether-Lumefantrine)
8. Drug of choice - Severe malaria: IV Artesunate (not quinine - 35% lower mortality)
9. Drug contraindicated in G6PD deficiency: Primaquine (+ tafenoquine)
10. Blackwater fever: Massive hemolysis + hemoglobinuria; switch from quinine to artesunate
11. Steroid in cerebral malaria: CONTRAINDICATED (proven harmful)
12. Hypoglycemia in malaria: Three groups at risk: children, pregnant women, quinine-treated patients
13. Quartan nephrotic syndrome: P. malariae in children
14. Most common complication in children: Severe anemia
15. Mosquito: Only female Anopheles, bites between dusk and dawn

Common Student Mistakes

Frequently Asked Viva Questions

P. falciparum-infected RBCs express PfEMP1 on knob-like surface projections. PfEMP1 binds ICAM-1, VCAM-1, and CD36 on cerebral endothelium (cytoadherence), causing microvascular obstruction. Combined with rosetting (infected + uninfected RBC clumping), this causes tissue hypoxia, blood-brain barrier disruption, and neuronal injury. Neuroinflammation via TNF-α and other cytokines amplifies the damage.

P. vivax (and P. ovale) sporozoites can develop into dormant hypnozoites in hepatocytes during the liver stage. These are not killed by chloroquine or ACTs (which only act on blood-stage parasites). Hypnozoites reactivate weeks to years later, causing relapse. P. falciparum does NOT form hypnozoites, so it cannot relapse - it can only recrudesce if blood-stage parasites persist.

Quinine stimulates pancreatic beta cells to release insulin (quinidine does this even more potently). Combined with the parasite's own high glucose consumption and impaired hepatic gluconeogenesis in severe malaria, this creates life-threatening hypoglycemia. This is why all quinine infusions must be given in 5-10% dextrose and glucose monitored Q1-2h.

Artemisinin compounds have an extremely short half-life (~1 hour). They rapidly reduce parasite biomass (by >99.9% within 48h through generation of free radicals that damage parasite membranes and proteins). But because they are cleared so quickly, residual parasites would survive and re-grow. The partner drug (lumefantrine, piperaquine, mefloquine, etc.) has a longer half-life and eliminates these remaining parasites, thereby preventing resistance and ensuring complete cure.

Massive intravascular hemolysis in falciparum malaria causing hemoglobinuria - the urine turns dark red to black (hence "blackwater"). Previously thought to be quinine-triggered, it can occur with any antimalarial. Can lead to AKI from hemoglobin toxicity to renal tubules. Management: switch from quinine to artesunate, IV fluids, monitor renal function, dialysis if AKI develops.

---

PART 17 - CASE-BASED LEARNING

CASE 1 - OPD Scenario

1. What is your top diagnosis and what features support it?
2. What investigations do you order in what priority?
3. His RDT comes back positive for P. falciparum. His blood glucose is 94 mg/dL, Hb 10.2 g/dL, platelets 82,000/µL, creatinine 1.1 mg/dL. Does he have uncomplicated or severe malaria?
4. What is your treatment plan?
5. What follow-up instructions do you give?

---

CASE 2 - Ward Scenario

1. What has happened? List at least 3 problems.
2. What is your immediate bedside action (next 2 minutes)?
3. Should you continue chloroquine? If not, what do you switch to?
4. What are the indications for ICU transfer here?
5. She is 12 weeks pregnant. Does this change your management?

---

CASE 3 - ICU Scenario

1. List all the criteria for severe malaria present in this child.
2. You have artesunate and quinine available. What do you choose and why?
3. His convulsions continue for 3 minutes. What drug and dose do you give?
4. What blood product and how much do you order?
5. His father asks: "Should we give him the steroid injection we brought from the pharmacy?" How do you respond and why?

---

PART 18 - VISUAL SUMMARY MIND MAP

                          M A L A R I A
                               │
     ┌─────────────────────────┼──────────────────────────┐
     │                         │                          │
  AGENT                  DIAGNOSIS                  MANAGEMENT
  5 species              ─────────                  ──────────
  P. falciparum          Blood film (GS)            Uncomplicated:
  (worst - PfEMP1)       Thick + Thin                 ACT × 3 days
  P. vivax               RDT (HRP2/LDH)             Vivax/Ovale:
  (hypnozoites)          PCR (species ID)              CQ + Primaquine
  P. ovale               qSOFA/SOFA if               Severe:
  (hypnozoites)          septic features               Artesunate IV
  P. malariae                │                         NOT quinine
  (recrudescence)      INVESTIGATIONS                NOT steroids
  P. knowlesi           Glucose STAT ←─────────────────────┐
     │                  CBC, RFT, LFT                       │
  CYCLE                 ABG, Coag                    ICU MANAGEMENT
  Sporozoite            ECG if quinine                MAP ≥65 mmHg
  → Liver (5-15d)                                    Glucose Q1-2h
  → Merozoites              COMPLICATIONS             Parasitemia Q12h
  → RBC → Fever        ─────────────────             Transfuse if Hb<7
  → Gametocytes        Cerebral malaria              Dialysis for AKI
                       Severe anemia                 Ventilate for ARDS
  PREVENTION           Blackwater fever
  ITNs (LLIN)          Hypoglycemia                  SPECIAL GROUPS
  IRS                  AKI, DIC, ARDS               Pregnancy: ACT safe
  Prophylaxis          Pulmonary edema               (2nd+3rd trimester)
  (ATQ-PG,Doxy,MQ)     Quartan nephropathy           Children <20kg:
  Vaccines:              (P. malariae)               3 mg/kg artesunate
  RTS,S & R21           HMS (vivax)                  G6PD: NO primaquine

---

SAFETY DISCLAIMER

For Educational Use Only. All treatment doses, drug selections, and clinical decisions described in this module are for learning purposes. Real patient management must be performed by a qualified, licensed physician with full knowledge of the patient's clinical status, local drug availability, antimalarial resistance patterns, and institutional protocols. Always verify drug doses against current formularies and WHO/national guidelines before prescribing. Drug choices and doses must be adjusted for patient weight, age, pregnancy status, G6PD status, renal function, and local resistance patterns.

• Complete life cycle with annotated diagram (Robbins Pathology)
• All 5 species compared in a single table with distinguishing blood film features
• Pathophysiology - exactly WHY each complication occurs (PfEMP1, cytoadherence, rosetting, cytokine storm)
• WHO severe malaria criteria with the "CAPS RHAHHH" mnemonic
• Complete treatment tables - ACT regimens, severe malaria artesunate dosing, special populations
• Full ICU protocol with hourly monitoring parameters
• OPD → Ward → ED → ICU protocols
• WHO 2025 guidelines + CDC 2024 guidelines incorporated
• 3 Case-based scenarios (OPD, Ward, ICU) with questions for you to reason through

---

• Mechanisms of drug action (how artemisinin works, why chloroquine fails)
• Malaria and G6PD deficiency in detail
• Blackwater fever management
• Antimalarial resistance - current crisis
• Malaria vs. other tropical fevers (differential diagnosis)
• Prescription writing for a specific scenario